Unknown PHASE2 INTERVENTIONAL 2-arm NCT01614938

Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer

Phase II Trial of Docetaxel-Cisplatin Neoadjuvant Chemotherapy Followed by Concurrent Radiotherapy With Cetuximab or Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma

Sponsor: Fudan University

Conditions Nasopharyngeal Carcinoma

Interventions Cetuximab Cisplatin Docetaxel Intensity-modulated radiotherapy

Updated 5 times since 2017 Last updated: Jun 6, 2012 Started: Aug 31, 2010 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01614938, this PHASE2 trial focuses on Nasopharyngeal Carcinoma and remains ongoing. Sponsored by Fudan University, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China